Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle

Chenyang Li; Xiuping Han

doi:10.1007/s11095-020-02838-4

ScienceGate Book Chapters

JOURNAL ARTICLE

Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle

Chenyang Li Xiuping Han

Year: 2020 Journal: Pharmaceutical Research Vol: 37 (6)Pages: 109-109 Publisher: Springer Science+Business Media

DOI: 10.1007/s11095-020-02838-4

Get Full-Text PDF Get Analytical Report

Keywords:

Cancer research Cytotoxic T cell PI3K/AKT/mTOR pathway Cell cycle Cancer Apoptosis Biology Carcinogenesis Cancer cell Immune checkpoint Immune system Immunotherapy Immunology In vitro

Metrics

Cited By

2.41

FWCI (Field Weighted Citation Impact)

Refs

0.89

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Cancer Immunotherapy and Biomarkers

Health Sciences → Medicine → Oncology

Immunotherapy and Immune Responses

Life Sciences → Immunology and Microbiology → Immunology

CAR-T cell therapy research

Health Sciences → Medicine → Oncology

Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle

Metrics

Citation History

Topics

Related Documents

PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment

PD-L1 siRNA–hyaluronic acid conjugate for dual-targeted cancer immunotherapy

PD-L1 Targeted Immunoliposomes with PD-L1 siRNA and HDAC Inhibitor for Anti-Lung Cancer Immunotherapy

Mitochondrial PD-L1 modulates cancer immunotherapy

A PD‐L1 siRNA‐Loaded Boron Nanoparticle for Targeted Cancer Radiotherapy and Immunotherapy